Skip to main content
TipRanks
Go Ultimate75% OFF

Addex Therapeutics (ADXN) AI Stock Analysis

2 Followers
CH:ADXN

Addex Therapeutics

(Six Swiss:ADXN)

Select Model
Rating:41Neutral
Price Target:CHF 0.02â–¼(-4.35% Downside)
Action:reiterated
Date:11/13/26

The overall score of 41 reflects a company in a precarious financial position with a weak stock price trend, partially offset by a moderately positive strategic outlook from its latest earnings call. The most significant factors are the severe financial distress, evidenced by a 97% revenue collapse and continuous cash burn, and a bearish technical profile with the stock trading below all major moving averages. The earnings call provides a glimmer of hope with an extended cash runway and a promising pipeline, but the immediate need for further financing and a dwindling cash balance remain critical risks.

Positive Factors
Expanded GABAB PAM rights and IPRegaining full rights gives Addex control over development and partnering decisions across a broad GABAB PAM portfolio. The associated patent filings, if granted, could provide lengthy intellectual-property protection and preserve strategic optionality across substance-use and other indications.
Negative Factors
Sharp revenue contraction and deep lossesContracting revenue alongside a deeply negative net margin shows that Addex has not yet established a self-sustaining commercial earnings base. Continued losses reduce internal funding capacity and leave future progress dependent on successful development outcomes, partnerships, or additional capital.

Addex Therapeutics (ADXN) vs. iShares MSCI Switzerland ETF (EWL)

-80%-60%-40%-20%0%20%40%CH:ADXN-57.41%EWL+11.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CHF 3.03M
Dividend Yield
―
Average Volume (3M)
1.37M
Price to Earnings (P/E)
-0.5
Beta (1Y)
0.81
Revenue Growth
-50.34%
EPS Growth
4.75%
Country
Switzerland
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Addex Therapeutics Business Overview & Revenue Model

Company Description

Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Base...

Addex Therapeutics Earnings Call Summary

Earnings Call Date:Sep 28, 2026(Q2-2026)|% Change Since:-4.17%|Next Earnings Date:May 20, 2020
Earnings Call SentimentPositive

The call was predominantly positive, with management highlighting $2.8 million of financing, a cash runway into Q4 2027, regained rights to the GABAB PAM platform, strong preclinical chronic cough data, and continued progress across the Neurosterix and Addex pipelines. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash usage, continued net losses, an increase in Addex's share of Neurosterix's loss, and the need to secure financing before starting chronic cough IND-enabling studies.

Positive Updates

ATM Financing and Extended Cash Runway
Addex raised $2.8 million through its ATM facility in Q3 2026, strengthening the balance sheet and providing cash runway into Q4 2027.

Negative Updates

Limited Cash Balance at Half-Year
Addex ended H1 2026 with CHF 0.8 million in cash, down CHF 0.8 million from CHF 1.6 million as of December 31, 2026, primarily due to operating costs and partially offset by the sale of treasury ADSs.

Company Guidance

Addex said it has $2.8 million raised through its ATM facility and now has a cash runway through into Q4 of 2027; it expects NTX-253 to complete phase I very soon and expects phase I data from the NTX-253 program in Q4 this year, while NTX-529 IND-enabling studies should start shortly and NTX-819 is expected to complete IND-enabling studies in the coming months. The next milestone for the SUD program is the filing of an IND, and for the cough program, the start of IND-enabling studies, which are planned and ready to start subject to securing financing. Addex is also preparing dipraglurant for phase II in post-stroke recovery, and said it is looking forward to completing the evaluation of potential indications for its mGlu2 PAM program and securing the financial resources to advance its portfolio into clinical studies.

Addex Therapeutics Financial Statement Overview

Summary

Financial performance is critically weak. Revenue has collapsed by over 97% to just $63K, net profit margin is deeply negative at -108.7%, and the company is burning cash consistently. The sole positive is a debt-free balance sheet, but equity is rapidly eroding, indicating a high risk of insolvency without new funding.

Income Statement

8Very Negative

Balance Sheet

45Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Dec 2022Dec 2021
Income Statement
Total Revenue63.19K173.00K410.04K1.61M1.42M2.92M
Gross Profit26.03K164.39K-444.26K-5.32M-13.20M-9.67M
EBITDA-3.44M-2.81M-4.65M-10.26M-20.43M-14.94M
Net Income-6.87M-6.73M7.06M-10.56M-20.80M-15.41M
Balance Sheet
Total Assets3.48M6.36M10.67M4.64M8.28M22.54M
Cash, Cash Equivalents and Short-Term Investments767.33K1.64M3.34M3.87M6.96M20.50M
Total Debt77.50K34.69K41.99K344.34K373.13K482.01K
Total Liabilities1.57M1.60M1.00M3.50M3.37M5.61M
Stockholders Equity1.90M4.76M9.67M1.15M4.91M16.93M
Cash Flow
Free Cash Flow-2.39M-2.17M-5.37M-8.00M-16.44M-14.74M
Operating Cash Flow-2.39M-2.17M-5.37M-7.99M-16.44M-14.71M
Investing Cash Flow56.67K-680.69K4.65M-6,8422,972-30.31K
Financing Cash Flow793.88K1.19M104.97K5.26M3.10M16.40M

Addex Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.02

Price Trends

50DMA0.02Negative
100DMA0.03Negative
200DMA0.04Negative

Market Momentum

MACD0.00Positive
RSI41.94Neutral
STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:ADXN, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of 0.00 indicates Positive momentum. The RSI at 41.94 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:ADXN.

Addex Therapeutics Risk Analysis

Addex Therapeutics disclosed 54 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We were an "emerging growth company" for the financial reporting published until December 31, 2025 and it is possible that investors have found or will continue to find shares or our ADSs less attractive.Q4, 2025
2.The value of our ADSs may be driven by the release of preclinical and clinical studies led by Neurosterix GroupQ4, 2024
3.Our Partner Janssen terminated the development of our drug candidate in epilepsy and returned to us this drug candidateQ4, 2024

Addex Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:ADXN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CH:ADXNCH:ADXN41NeutralCHF 3.13M-0.51-204.04%―-50.34%4.75%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%CH:ADXNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:ADXN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CH:ADXNAddex Therapeutics Ltd0.02-0.03-56.60%

Addex Therapeutics Corporate Events

Addex to Report Third-Quarter 2026 Results and Corporate Update

Nov 20, 2026

Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule allosteric modulators for neurological disorders, including dipraglurant for potential brain-injury recovery applications and GABAB PAM candidates for su...

Neurosterix Closes $105 Million Series B Financing

Nov 11, 2026

Addex Therapeutics, a clinical-stage biopharmaceutical company developing small-molecule allosteric modulators for neurological disorders, said its spin-out Neurosterix closed a $105 million Series B financing. Addex did not participate, and its equi...

Addex Boosts Issued Share Capital to Enhance Financing Flexibility

Oct 29, 2026

Addex Therapeutics has issued and fully subscribed 93 million new registered shares, each with a nominal value of CHF 0.01, through its wholly owned subsidiary Addex Pharma S.A., with the new shares listed on the SIX Swiss Exchange. The move raises t...

Addex Spin-Out Neurosterix Advances Schizophrenia Drug NTX-253 Into Phase 2

Oct 8, 2026

Addex Therapeutics reported that its spin-out Neurosterix has completed Phase 1 clinical studies of NTX-253, a positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia, and plans to move the candidate into Phase 2...

Addex Therapeutics Brings Back Veteran Chemist to Lead Pharmaceutical Development as Pipeline Enters New Phase

Oct 2, 2026

Addex Therapeutics has appointed veteran medicinal chemist Jean‑Philippe Rocher as Head of Pharmaceutical Development and member of the executive team, while Mikhail Kalinichev steps down as Head of Translational Science to focus on his role at spin‑...

Addex Raises Fresh Funds as It Regains GABAB Rights and Advances CNS Pipeline

Sep 28, 2026

Addex Therapeutics reported its 2026 half-year results, highlighting a tighter financial position alongside strategic progress in its neurology-focused pipeline. The company’s cash and cash equivalents fell to CHF 0.8 million from CHF 2.3 million a y...

Addex Regains Global Rights to Key GABAB Assets, Expands Neurology Portfolio

Sep 25, 2026

Addex Therapeutics has regained full global rights to all GABAB positive allosteric modulator assets previously under collaboration with Indivior, following Indivior’s strategic refocus and planned merger with Supernus Pharmaceuticals, Inc. The move...

Addex to Present Half-Year Results and Pipeline Update

Sep 24, 2026

Addex Therapeutics, a clinical-stage biopharmaceutical group listed on SIX and Nasdaq under the ticker ADXN, focuses on small molecule allosteric modulators for neurological and psychiatric conditions and holds strategic interests in external program...

Addex Raises USD 2.8 Million, Extends Cash Runway to Late 2027

Aug 26, 2026

Addex Therapeutics, a clinical-stage biopharma focused on small molecule allosteric modulators for neurological diseases, is developing dipraglurant for brain injury recovery and advancing GABAB programs for substance use disorders and chronic cough,...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026